A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia
References (114)
Cholesterol reduction and its impact on coronary artery disease and total mortality
Am J Cardiol
(1995)- et al.
Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin
J Am Coll Cardiol
(1986) - et al.
Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals
Am J Med
(1996) - et al.
Distribution of lipids in 8500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group
Am J Cardiol
(1995) - et al.
for the CURVES Investigators. Comparative dose efficacy of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study)
Am J Cardiol
(1998) - et al.
Efficacy safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study
Atherosclerosis
(1990) - et al.
Efficacy safety of pravastatin in patients with primary hypercholesterolemia. II. A dose-response study
Atherosclerosis
(1990) - et al.
Dosedependent hypolipidemic effect of an inhibitor of HMG-CoA reductase pravastatin (CS-514) in hypercholesterolemic subjects. A double blind test
Atherosclerosis
(1988) - et al.
An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease
Am J Cardiol
(1991) - et al.
Longterm efficacy and safety of atorvastatin compared to lovastatin in hypercholesterolemic patients
Am J Cardiol
(1997)
A multicenter, double-blind, 1 year study comparing the safety and efficacy of once daily atorvastatin with that of simvastatin in patients with hypercholesterolemia
Am J Cardiol
(1997)
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
Atherosclerosis
(1997)
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day
Am J Cardiol
(1997)
Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition
Metabolism
(1995)
Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia
Am J Med
(1993)
Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia
Am J Cardiol
(1995)
Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia
Am J Cardiol
(1994)
Fluvastatin with and without niacin for hypercholesterolemia
Am J Cardiol
(1994)
Longterm efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156 week multicenter study)
Am J Cardiol
(1995)
Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: A 3-year follow-up
Atherosclerosis
(1990)
Cholesterol reduction yields clinical benefit
Circulation
(1998)
Lipid lowering regression coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, 7th Council Meeting
Circulation
(1995)
The value of lowering cholesterol after myocardial infarction
NEJM
(1990)
Reduction in incidence of coronary heart disease
JAMA
(1984)
The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
JAMA
(1984)
Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
JAMA
(1987)
Randomized trial of cholesterol-lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
Lancet
(1994)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
NEJM
(1996)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
NEJM
(1995)
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
JAMA
(1993)
Guidelines for using serum cholesterol, highdensity lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults
Ann Intern Med
(1996)
Cholesterol agonistics
Ann Intern Med
(1996)
The cholesterol population model: US population requirements for treatment of hypercholesterolemia
Am J Managed Care
(1996)
Inadequate treatment with HMG-CoA reductase inhibitors by health care providers
Am J Med
(1996)
Dose-response characteristics of cholesterol-lowering drug therapies: Implications for treatment
Ann Intern Med
(1996)
Cost-effectiveness of hypolipidaemic drugs
Postgrad Med J
(1993)
The cost of screening for hypercholesterolaemia-results from a clinical trial in Swedish primary health care
Scand J Clin Lab Invest
(1993)
Strategies for reducing coronary risk factors in primary care: Which is most cost effective?
BMJ
(1995)
Cost-effectiveness of accepted measures for intervention in coronary heart disease
Coron Artery Dis
(1995)
The efficacy of dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia
NEJM
(1993)
Cholesterol-lowering intervention program: Effect of the Step I diet in community practice
Arch Intern Med
(1996)
Declining serum total cholesterol levels among US adults: The National Health and Nutrition Examination Surveys
JAMA
(1993)
Combination drug therapy for hypercholesterolemia. The trade-off between cost and simplicity
Arch Intern Med
(1993)
CholesterolReduction Intervention Study: A randomized trial to assess effectiveness and costs in clinical practice
Arch Intern Med
(1996)
TM Average Wholesale Prices
(1998)
Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
Arch Intern Med
(1991)
Pravastatin therapy in primary moderate hypercholesterolemia: Changes in metabolism of apolipoprotein B-containing lipoproteins
J Intern Med
(1990)
Lipid control with low-dosage simvastatin in patients with moderate hypercholesterolemia. An Italian multicentre doubleblind placebo-controlled study
Eur Heart J
(1992)
Simvastatin in severe hypercholesterolemia: A placebo controlled trial
Br J Clin Pharmacol
(1991)
Efficacy safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database
Am J Hypertens
(1993)
Cited by (30)
Stem-bark of Terminalia arjuna attenuates human monocytic (THP-1) and aortic endothelial cell activation
2013, Journal of EthnopharmacologyCitation Excerpt :Hypolipidaemic and antioxidant nature of TA-stem bark has been reported in animal models (Tiwari et al., 1990, Shaila et al., 1998; Gauthaman et al., 2001; Gupta et al., 2001; Verma and Vinaya, 2009). In the present study, both the extracts of TA-stem (TAAE and TAWE) were found to inhibit the activity of HMG-CoA reductase (Fig. 3), a key enzyme in sterol biosynthesis and often targeted for developing cholesterol lowering drugs (Daniel et al., 1999). In view of proinflammatory nature of lypolysis products generated from very low density lipoproteins (Higgins and Rutledge, 2009; Tetali et al., 2010), the inhibition of LpL is desirable.
Copyright © 1997 Published by Elsevier Inc.